On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint. The trial was conducted outside the United States, primarily in Eastern Europe. In the trial’s preliminary results, both active and placebo studies showed similar reductions in focal seizures of approximately 40 percent. The extent of the placebo response was substantially greater than that seen in published studies of other treatments in similar patient populations and GW is now working to understand the potential reasons for the results.
Compound GWP42006 had, in the past, shown anti-epileptic properties across a range of in vitro and in vivo models of epilepsy. GW plans to continue exploring potential development opportunities for this compound in the field of epilepsy. In parallel with the failed study, the company has also been evaluating GWP42006 in clinical models on ASD (Autism) with promising results for cognitive and social symptoms as well as repetitive behavior. However, according to company executives, GW’s top priority in 2018 will remain Epidiolex which is currently under regulatory review in the U.S. and Europe and is expected to launch later this year in the U.S. Epidiolex has been shown to effectively treat symptoms in a variety of rare epileptic conditions.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
You may be interested
CashCropToday | Joint Venture Interviews Justin Braune Part 1Ricky M - September 18, 2018
In this episode of Joint Venture, Michael Parker sits down with Justin Braine, Blunt Capital Co. Advisor, to discuss bridging the gap between Cannabis & Hemp Entrepreneurs…
CannTrust Completes First Shipment of Cannabis Oil to Denmark Partner STENOCAREEditor - September 18, 2018
CannTrust Holdings Inc. (TSX :TRST ) announced this morning that the company has completed its first international shipment of cannabis oils based products to STENOCARE, a Danish company…
Canopy Growth’s Tweed Farms Receives Additional Licensing for Cannabis ProductionEditor - September 17, 2018
Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) announced this morning that their Tweed Farms cannabis cultivation operation has received an amendment to their license which will approve…